Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis.

Acquati F, Lualdi M, Bertilaccio S, Monti L, Turconi G, Fabbri M, Grimaldi A, Anselmo A, Inforzato A, Collotta A, Cimetti L, Riva C, Gribaldo L, Ghia P, Taramelli R.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8140-5. doi: 10.1073/pnas.1222079110. Epub 2013 Apr 29.

PMID:
23630276
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase.

Acquati F, Bertilaccio S, Grimaldi A, Monti L, Cinquetti R, Bonetti P, Lualdi M, Vidalino L, Fabbri M, Sacco MG, van Rooijen N, Campomenosi P, Vigetti D, Passi A, Riva C, Capella C, Sanvito F, Doglioni C, Gribaldo L, Macchi P, Sica A, Noonan DM, Ghia P, Taramelli R.

Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1104-9. doi: 10.1073/pnas.1013746108. Epub 2010 Dec 28.

PMID:
21189302
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts.

Schauer IG, Zhang J, Xing Z, Guo X, Mercado-Uribe I, Sood AK, Huang P, Liu J.

Neoplasia. 2013 Apr;15(4):409-20.

PMID:
23555186
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tumor and metastasis suppression by the human RNASET2 gene.

Acquati F, Possati L, Ferrante L, Campomenosi P, Talevi S, Bardelli S, Margiotta C, Russo A, Bortoletto E, Rocchetti R, Calza R, Cinquetti R, Monti L, Salis S, Barbanti-Brodano G, Taramelli R.

Int J Oncol. 2005 May;26(5):1159-68.

PMID:
15809705
[PubMed - indexed for MEDLINE]
5.

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.

Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang HF, Zeng Q.

BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.

PMID:
23418787
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Molecular signature induced by RNASET2, a tumor antagonizing gene, in ovarian cancer cells.

Acquati F, Monti L, Lualdi M, Fabbri M, Sacco MG, Gribaldo L, Taramelli R.

Oncotarget. 2011 Jun;2(6):477-84. Review.

PMID:
21646684
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.

Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS.

Oncogene. 2011 Aug 11;30(32):3522-36. doi: 10.1038/onc.2011.70. Epub 2011 Mar 21.

PMID:
21423204
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.

Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP.

Clin Cancer Res. 2005 Oct 15;11(20):7243-54.

PMID:
16243794
[PubMed - indexed for MEDLINE]
Free Article
9.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB.

J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42. doi: 10.1093/jnci/djn378. Epub 2008 Nov 11.

PMID:
19001604
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Implantation and growth of epidermal growth factor (EGF) receptor expressing human ovarian cancer xenografts in nude mice is dependent on EGF.

Kurachi H, Morishige K, Adachi H, Adachi K, Tasaka K, Sawada M, Miyake A.

Cancer. 1994 Dec 1;74(11):2984-90.

PMID:
7954262
[PubMed - indexed for MEDLINE]
11.

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK.

Oncogene. 2009 Jan 15;28(2):209-18. doi: 10.1038/onc.2008.374. Epub 2008 Oct 6.

PMID:
18836486
[PubMed - indexed for MEDLINE]
12.

Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.

Leong CT, Ong CK, Tay SK, Huynh H.

Oncogene. 2007 Feb 8;26(6):870-80. Epub 2006 Jul 24.

PMID:
16862170
[PubMed - indexed for MEDLINE]
13.

Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.

Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, Singh RK, Raphael BJ, Brard L, Brodsky AS.

BMC Cancer. 2011 Jul 22;11:308. doi: 10.1186/1471-2407-11-308.

PMID:
21781307
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.

Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C, Krainer M.

Mol Cancer Res. 2005 Jun;3(6):335-43.

PMID:
15972852
[PubMed - indexed for MEDLINE]
Free Article
15.

WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.

Yoshioka S, King ML, Ran S, Okuda H, MacLean JA 2nd, McAsey ME, Sugino N, Brard L, Watabe K, Hayashi K.

Mol Cancer Res. 2012 Mar;10(3):469-82. doi: 10.1158/1541-7786.MCR-11-0177. Epub 2012 Jan 9.

PMID:
22232518
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.

Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z.

Cancer Biol Ther. 2010 Oct 15;10(8):788-95. Epub 2010 Oct 15.

PMID:
20686362
[PubMed - indexed for MEDLINE]
Free Article
17.

Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2.

De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, Oggionni M, Bertuletti N, Ditto A, Raspagliesi F, Pilotti S, Pierotti MA, Canevari S, Schneider C.

Oncogene. 2004 Oct 21;23(49):8171-83.

PMID:
15377994
[PubMed - indexed for MEDLINE]
18.

Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin-polyethyleneimine nanogels.

Liu P, Gou M, Yi T, Xie C, Qi X, Zhou S, Deng H, Wei Y, Zhao X.

Oncol Rep. 2012 Feb;27(2):363-70. doi: 10.3892/or.2011.1550. Epub 2011 Nov 11.

PMID:
22086394
[PubMed - indexed for MEDLINE]
19.

Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.

Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W.

Clin Cancer Res. 2005 Jan 1;11(1):323-8.

PMID:
15671562
[PubMed - indexed for MEDLINE]
Free Article
20.

Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.

Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ.

PLoS One. 2012;7(1):e29079. doi: 10.1371/journal.pone.0029079. Epub 2012 Jan 17.

PMID:
22272227
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk